Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 6/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18580942 | 0.89 | TSHR (0.48) | MEN1KMT2AALDH1A1L3MBTL1TSHR | |
| SCHEMBL18581192 | 0.89 | TSHR (0.48) | MEN1KMT2AALDH1A1L3MBTL1TSHR | |
| SCHEMBL18580944 | 0.89 | TSHR (0.48) | MEN1KMT2AALDH1A1L3MBTL1TSHR | |
| SCHEMBL21972609 | 0.88 | KMT2A (0.57) | MEN1KMT2AALDH1A1L3MBTL1TSHR | |
| SCHEMBL18581115 | 0.88 | HDAC6 (0.51) | MEN1KMT2AALDH1A1L3MBTL1TSHR | |
| SCHEMBL18581042 | 0.88 | TSHR (0.52) | MEN1KMT2AALDH1A1L3MBTL1TSHR | |
| SCHEMBL21972612 | 0.81 | TSHR (0.47) | MEN1KMT2AALDH1A1L3MBTL1TSHR | |
| SCHEMBL18581865 | 0.81 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1L3MBTL1TSHR | |
| SCHEMBL2821928 | 0.79 | REN (0.52) | MEN1KMT2AALDH1A1L3MBTL1TSHR | |
| SCHEMBL18593278 | 0.78 | TSHR (0.47) | MEN1KMT2AALDH1A1TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180354919-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354919-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | MEN1 3243/4885KMT2A 48/4885ALDH1A1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.